New drug shows promise for nasal polyps in chinese patients

NCT ID NCT05878093

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the drug dupilumab in 63 Chinese adults with chronic sinusitis and nasal polyps. Participants received either dupilumab injections or a placebo, plus a standard nasal steroid spray, for 24 weeks. The main goal was to see if dupilumab could shrink nasal polyps and improve congestion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dupilumab (injectable drug) plus budesonide nasal spray
What this could lead to: If successful, this could provide a new treatment option for Chinese adults with nasal polyps that reduces polyp size and eases congestion.
What could go wrong: This is a small Phase 3 trial (63 participants) and results may not apply to all patients. Dupilumab can cause injection site reactions and allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

Contacts and locations

Locations

Investigational Site Number : 1560001

Beijing, 100730, China
Investigational Site Number : 1560004

Hangzhou, 310003, China
Investigational Site Number : 1560005

Beijing, 100044, China
Investigational Site Number : 1560006

Hefei, 230001, China
Investigational Site Number : 1560007

Wuhan, 430022, China
Investigational Site Number : 1560009

Yantai, 264000, China
Investigational Site Number : 1560010

Chengdu, 610041, China
Investigational Site Number : 1560011

Guangzhou, China
Investigational Site Number : 1560012

Guangzhou, 510163, China
Investigational Site Number : 1560013

Qingdao, China
Investigational Site Number : 1560014

Chongqing, 400016, China
Investigational Site Number : 1560016

Jinan, 250102, China
Investigational Site Number : 1560017

Shanghai, 200065, China
Investigational Site Number : 1560018

Taiyuan, 030001, China
Investigational Site Number : 1560020

Zibo, 255036, China
Investigational Site Number : 1560021

Wuhan, 430060, China
Investigational Site Number : 1560022

Fuzhou, 350005, China
Investigational Site Number : 1560025

Jingzhou, 434020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.